Last edition
News about "Dr. Jingsong Wang"
Harbour BioMed Reports Promising Preclinical Data for AI-Driven Drug Candidate LET003
Harbour BioMed announced promising preclinical data for LET003, its first Artificial Intelligence (AI)-enabled drug candidate, highlighting potential as a next-generation obesity therapy targeting ACVR2A/2B.
Dr. Jingsong Wang | 18/05/2026 | By News Bureau | 280
Harbour BioMed Secures FDA IND Clearance for HBM7004 in Advanced Solid Tumors
Harbour BioMed receives US Food and Drug Administration (FDA) IND clearance for HBM7004, a novel B7H4xCD3 bispecific antibody developed on its HBICE platform for advanced solid tumors.
Dr. Jingsong Wang | 11/05/2026 | By News Bureau
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Dr. Jingsong Wang | 19/01/2026 | By News Bureau | 199
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy